Table 1 Baseline characteristics of all patients in the follow up cohort
Number of patients | 147 |
|---|---|
Age, years (mean, sd*) | 58 (12) |
Female, No (%) | 101 (69) |
Weight, kg (mean, sd) | 73 (14) |
Disease duration, years (mean, sd) | 11 (7) |
RF positive, No (%) | 117 (81) |
Anti-CCP positive, No (%) | 95 (69) |
DAS28 at inclusion (mean, sd) | 3.5 (1.3) |
Interval duration at inclusion, weeks (median, IQR) | |
Previous DMARDs, weeks (median, IQR**) | |
Concomitant DMARD use, No (%) | 111 (78) |
Concomitant MTX use, No (%) | 95 (67) |
Previous anti-TNF-alpha therapy, No (%) | 16 (11) |
Duration of infliximab therapy, years (mean, sd) | 2.5 (2.0) |